Skip to content
Search

Latest Stories

Indian court offers temporary protection for Byju's

A group of shareholders requested an extraordinary general meeting (EGM) set for Friday (23) to oust Byju Raveendran.

Indian court offers temporary protection for Byju's

INDIAN edtech firm Byju's said Wednesday (21) a court had given it temporary protection in its fight against a group of shareholders trying to sack the company's billionaire founder.

Byju's, which is controlled by CEO Byju Raveendran, was once one of India's most valuable start-ups as demand for its online learning products boomed during the Covid pandemic.


Once valued at over $20 billion (£15.8bn), Byju's has seen its valuation crash by an estimated 90 per cent over the last year.

It lost support of key investors and has faced a series of crises, including the resignation of its auditor Deloitte and a legal fight with US lenders over a $1.2bn (£950 million) loan.

Earlier this month, a group of shareholders, including tech investor giant Prosus, requested an extraordinary general meeting (EGM) set for Friday (23) to oust Raveendran and appoint a new board.

But Byju's said a high court in India's Karnataka state had ordered that any decisions taken by shareholders at the EGM would be "invalid" until the next hearing.

Byju's said the reason for the EGM were "merely a smokescreen designed to disrupt the management, control, and functioning of the company".

AFP has reviewed a copy of the interim order.

Investor sources said that the court order did not prohibit the shareholder meeting from taking place or declare it illegal.

The sources added that the EGM would go ahead and investors would still push to remove Raveendran as CEO.

Byju's has alleged that investors, including US growth equity firm General Atlantic and the Chan Zuckerberg Initiative, a philanthropic venture founded by Facebook boss Mark Zuckerberg and his wife Priscilla Chan, had violated their shareholders' agreement by calling the EGM.

Representatives of Prosus and the Chan Zuckerberg Initiative stepped down from the Byju's board last year.

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less